93MO Overall survival (OS) results by age subgroup from the phase III MONALEESA-7 (ML-7) trial of premenopausal patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)
| Autor: | Lu, Y-S., El Saghir, N.S., Hurvitz, S.A., Tripathy, D., Cardoso, F., Colleoni, M.A., Campos-Gomez, S., Franke, F.A., Oregan, R., Wang, C., Wang, Y., Zarate, J.P., Chakravartty, A., Im, S-A. |
|---|---|
| Zdroj: | In Annals of Oncology May 2021 32 Supplement 2:S62-S62 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|